Carolyn Buser-Doepner
Overview
Explore the profile of Carolyn Buser-Doepner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
1065
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Behan F, Iorio F, Picco G, Goncalves E, Beaver C, Migliardi G, et al.
Nature
. 2019 Apr;
568(7753):511-516.
PMID: 30971826
Functional genomics approaches can overcome limitations-such as the lack of identification of robust targets and poor clinical efficacy-that hamper cancer drug development. Here we performed genome-scale CRISPR-Cas9 screens in 324 ...
2.
Arrowsmith C, Audia J, Austin C, Baell J, Bennett J, Blagg J, et al.
Nat Chem Biol
. 2015 Oct;
11(11):887.
PMID: 26485080
No abstract available.
3.
Arrowsmith C, Audia J, Austin C, Baell J, Bennett J, Blagg J, et al.
Nat Chem Biol
. 2015 Jul;
11(8):536-41.
PMID: 26196764
No abstract available.
4.
Wang L, Mason K, Ang K, Buchholz T, Valdecanas D, Mathur A, et al.
Invest New Drugs
. 2011 Dec;
30(6):2113-20.
PMID: 22127459
The poly-(ADP-ribose) polymerase (PARP) inhibitor, MK-4827, is a novel potent, orally bioavailable PARP-1 and PARP-2 inhibitor currently in phase I clinical trials for cancer treatment. No preclinical data currently exist...
5.
Lamb J, Zhang C, Xie T, Wang K, Zhang B, Hao K, et al.
PLoS One
. 2011 Jul;
6(7):e20090.
PMID: 21750698
Background: In hepatocellular carcinoma (HCC) genes predictive of survival have been found in both adjacent normal (AN) and tumor (TU) tissues. The relationships between these two sets of predictive genes...
6.
Bilodeau M, Balitza A, Koester T, Manley P, Rodman L, Buser-Doepner C, et al.
J Med Chem
. 2004 Nov;
47(25):6363-72.
PMID: 15566305
A series of N-(1,3-thiazol-2-yl)pyridin-2-amine KDR kinase inhibitors have been developed that possess optimal properties. Compounds have been discovered that exhibit excellent in vivo potency. The particular challenges of overcoming hERG...